Drugs / pitrakinra
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00535028 | Jan → May 2005 | allergic asthma | Aerovance, Inc. | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pitrakinra | “Our aim was to assess the therapeutic effect of pitrakinra, an interleukin-4 variant that targets allergic Th2 inflammation by potently inhibiting the binding of interleukin 4...” PMID 17950857 ↗ Oct 2007 |
| Action | Inhibit | “potently inhibiting the binding of interleukin 4 and interleukin 13 to interleukin-4Ralpha receptor complexes” PMID 17950857 ↗ Oct 2007 |
| Modality | Protein / enzyme biologic | “pitrakinra, an interleukin-4 variant” PMID 17950857 ↗ Oct 2007 |
| Route | Subcutaneous | “by subcutaneous injection” PMID 17950857 ↗ Oct 2007 |